Mary Haak-Frendscho

Mary Haak-Frendscho was the founder of Compugen, Inc. (United States), founded in 2012, where the title held was Chairman from 2012 to 2016.
Current jobs include President, Chief Executive Officer & Director at Spotlight Therapeutics, Inc. since 2019; Director at Sirenas LLC since 2015; Director at Surrozen Operating, Inc. since 2021; and Independent Director at Surrozen, Inc. since 2021.
Former jobs include Chief Executive Officer & Director at Igenica Biotherapeutics, Inc. from 2012 to 2014; Chief Executive Officer & Director at Blueline Bioscience from 2016 to 2019; Director at Northern Biologics, Inc.; Principal at Genentech, Inc.; Principal at Abgenix, Inc.; Chief Scientific Officer, VP-Preclinical R&D at XOMA Royalty Corp.; President & Chief Scientific Officer at Takeda California, Inc. from 2008 to 2012; and Venture Partner at Versant Ventures Canada Ltd. from 2017 to 2019.
Education includes graduate degrees from the University of Washington and Stony Brook University, a doctorate from the University of Wisconsin, and an undergraduate degree from the University of Michigan.